Initiator Pharma A/S OMXSTO:INIT:
RECEIVES UK CTA APPROVAL TO INITIATE PHASE 2A STUDY IN VULVODYNIA
FIRST PATIENTS EXPECTED TO BE ENROLLED IN Q4 2025
Initiator Pharma Gets UK CTA Approval For Phase 2a Study
Earlier from Initiator Pharma
- Initiator Pharma A/S: Quarterly Trading Report 2025 Q3
- INIT: Pudafensine advances to Phase II for vulvodynia, targeting major unmet needs in women's health
- INIT: Pudafensine advanced to Phase IIa for vulvodynia, with strong funding and reduced Q2 losses
- INIT: Q1 2025 saw reduced losses and clinical progress in ED, FSD, and pain programs
- INIT: Reduced losses and clinical progress in ED and FSD position Initiator Pharma for future growth
Later from Initiator Pharma
- INIT: First-in-class therapy for vulvodynia enters pivotal trial, targeting a multibillion-euro market
- INIT: Advanced clinical pipeline and secured major financing, with focus on vulvodynia and ED markets
- Initiator Pharma to attend J.P. Morgan Healthcare Conference in San Francisco
- Initiator Pharma Granted European Patent For Pudafensine in FSD
- Initiator Pharma (Q4 Review): Dosing underway in phase IIa study
Follow Initiator Pharma into a list and get an email when it puts out news.
Follow Initiator Pharma